20
2019-12
On December 20, 2019, Future Top 100 Medical Enterprises Meeting of 2019 under the theme of “New Life Increment” was kicked off in Beijing· Jiuhua Villa. The meeting focused on multiple factors such as policy environment, technology environment and demanding spaces, provided comprehensive interpretation of the future development trend of health care industry to promote the reform of innovative health care industry.
13
2019-12
Ms. Lu Yan Serves as Kintor's Chief Financial Officer
[Suzhou, December 13, 2019] Kintor Pharmaceutical Limited and its subsidiaries (the "Group") officially announced the appointment of Ms. Lu Yan as Chief Financial Officer who would be responsible for our capital market strategy, financial planning, investor relations and internal controls
25
2019-10
[Suzhou, China, October 25, 2019] Kintor Pharmaceutical Limited (the parent company of Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor")) and its subsidiaries (the "Group")announced completion of a financing of USD45 million in September 2019, which was a new round of financing after Series C investment of RMB288 million in February 2018. This round of investment was led by the Shanghai Free Trade Zone Fund, followed by Huajin Capital, CCB Technological Innovation Fund, Yicheng Hongtai, Yirongchuang and Guangzhou Chengfa. The original investor, Highlight Medical, also participated in this round of investment.
29
2019-08
How Many Blockbuster Novel Drugs Can Be Produced for Chinese Hair Loss Population of 250 Million?
Recently, a group of data indicating more than 250 million people with hair loss in China has circulated online and caused heated discussion. In fact, hair loss is a common disease worldwide. Under normal circumstances, a healthy person will have nearly a hundred hairs shed naturally every day, and an equal amount of hair will be reborn from the scalp hair follicles. If hair loses faster than growth of newborn hair, there will be hair loss problem, which will affect the aesthetics and mental health.
20
2019-08
mTOR Inhibitor Developed by Suzhou Kintor Obtained Approval for Clinical Trials in China
[Suzhou, August 20, 2019] National Medical Products Administration officially granted a clinical trial approval to Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor") on commencement of clinical trials of the drug (GT0486) as an mTOR inhibitor. The drug (GT0486) is a novel mTORC1 / mTORC2 inhibitor (the second generation of mTOR inhibitor) which is indicated for advanced solid tumors. Currently, there is no second generation of mTOR inhibitors on the market in China, and there are huge unmet clinical needs in the research area.
19
2019-08
[Suzhou, August 19, 2019]Suzhou Kintor Pharmaceuticals, Inc. (“Suzhou Kintor") and CMAB Biopharma (Suzhou) Inc. ("CMAB") announced together a comprehensive strategic cooperation agreement on the development and production of ALK-1 monoclonal antibody in Suzhou Biopharma Industrial Park (BioBAY).
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn